PT-141
Proper Handling
- Specifications: Lyophilized powder in 3 mL vial. Purity (>98%) meets or exceeds U.S. Pharmacopeia (USP) and National Formulary (USP-NF) regulations.
- Directions: Reconstitute with Bacteriostatic Water prior to use. Schedule a wellness consult or speak with your healthcare provider for proper dosage.
- Storage: In lyophilized form, the peptide is stable for 36 months. Protect from light. Refrigerate and use within 45 days after opening or reconstituting to prevent loss of potency.
Need to speak with a clinician?
Schedule a wellness consultation with a practitioner specialized in peptide therapy, who will determine the best plan for you.
Compounded drugs, medications, and peptides for clinical research are not FDA-approved. Soma has ensured quality, safety and efficacy by performing RP-HPLC, MS, sterility and additional testing that meets or exceeds U.S. Pharmacopeia (USP) and National Formulary (USP-NF) regulations. All peptides are third-party tested with a Certificate of Analysis (COA) that is publicly available. Third party testing verifies that the product complies with the mandates of all relevant regulatory agencies.
PT-141 (Bremelanotide) is known to increase libido & intensity in both men and women. Rekindle and reconnect intimately, with minimal to no side effects*. Maximizes blood flow. Heightens experience and satisfaction, increases connection and intimacy, enhances sensitivity, targets specific receptors that control sexual function, and increases natural lubrication.
CAS Number 189691-06-3
PubChem CID 9941379
Molecular Weight 1025.2 g/mol
Molecular Formula C50H68N14O10
Synonyms Bremelanotide, PT 141, PT-141, PT141, Brmelanotice, BREMELANOTIDE, BREMELANOTIDE PT141, Bremelanotide, PT141, PT141 Acetate, BreMelanotide Acetate
Storage (Lyophilized) At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years
This product is sold as a pure compound for research purposes only, unless prescribed by a licensed physician. This product comes in the form of lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Please refer to our terms and conditions prior to purchase.
Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.
The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.
- Pfaus, J., Giuliano, F., & Gelez, H. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. The journal of sexual medicine, 4 Suppl 4, 269–279. https://doi.org/10.1111/j.1743-6109.2007.00610.x
- National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9941379, Bremelanotide. Retrieved August 10, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Bremelanotide.
- Molinoff, P. B., Shadiack, A. M., Earle, D., Diamond, L. E., & Quon, C. Y. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102. https://doi.org/10.1111/j.1749-6632.2003.tb03167.x
- Renquist, B. J., Lippert, R. N., Sebag, J. A., Ellacott, K. L., & Cone, R. D. (2011). Physiological roles of the melanocortin MC₃ receptor. European journal of pharmacology, 660(1), 13–20. https://doi.org/10.1016/j.ejphar.2010.12.025
- Adan, R. A., Tiesjema, B., Hillebrand, J. J., la Fleur, S. E., Kas, M. J., & de Krom, M. (2006). The MC4 receptor and control of appetite. British journal of pharmacology, 149(7), 815–827. https://doi.org/10.1038/sj.bjp.0706929
- Pfaus, J. G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10201–10204. https://doi.org/10.1073/pnas.0400491101
- Vemulapalli, R., Kurowski, S., Salisbury, B., Parker, E., & Davis, H. (2001). Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO. British journal of pharmacology, 134(8), 1705–1710. https://doi.org/10.1038/sj.bjp.0704437
- Thurston, L., Hunjan, T., Mills, E. G., Wall, M. B., Ertl, N., Phylactou, M., Muzi, B., Patel, B., Alexander, E. C., Suladze, S., Modi, M., Eng, P. C., Bassett, P. A., Abbara, A., Goldmeier, D., Comninos, A. N., & Dhillo, W. S. (2022). Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. The Journal of clinical investigation, 132(19), e152341. https://doi.org/10.1172/JCI152341
Buy It With
Frequently Asked Questions
PT-141
-
PT-141 (also called bremelanotide) is an FDA-approved synthetic peptide hormone that can be used to treat sexual dysfunction in both men and women. Unlike treatments that affect the vascular system, PT-141 affects the nervous system, so it not only increases blood flow to the penis or vagina and clitoris, but it also helps increase sexual desire.
-
Erectile dysfunction (ED) can be caused by many factors, including medical conditions, mental illness, or certain medications. There are many types of treatment for ED, but some can cause serious side effects.
PT-141 causes your brain to release nitric oxide, which relaxes the muscles of the penis and increases blood flow to the region.
This increase in blood flow can help men with ED achieve an erection.
-
One thing that makes PT-141 stand out is that it can be used for both men and women. It has been found to improve sexual desire in premenopausal women diagnosed with sexual arousal disorder.
While PT-141 primarily addresses sexual desire and intimacy, some women have reported improvements in overall well-being during menopause, including mood enhancement and a reduction in sexual discomfort. It’s essential to consult with a healthcare provider to determine the suitability of PT-141 for managing specific menopausal symptoms.
-
Customers have reported PT-141 working within 30 minutes. PT-141 acts quickly, often within just a few hours after administration. Unlike some traditional treatments that require weeks or months to show results, PT-141 works promptly.
-
PT-141 is commonly injected subcutaneously, making its use at risk for local redness, irritation, itching and swelling of the injection site.
Possible reported side effects of PT-141:
- Flushing
- Headache
- Nausea
It is important to consult with a medical professional prior to starting PT-141.
Remember, everyone reacts differently to substances like PT-141 due to individual physiological differences such as metabolism rate and overall health status. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away. Tell your doctor if you have any side effects.
-
PT-141 is an injectable peptide administered subcutaneously through the fat. The most fatty parts of the body are the abdomen, side or back of upper arms, and front of thighs.
Nasal sprays, oral pills, and creams have not shown to be an effective means in which to administer PT-141.
Schedule a wellness consultation to determine the best plan for your health.
-
Yes, PT-141, also known as the intranasal spray formulation of bremelanotide, is FDA-approved as a melanocortin agonist for the treatment of sexual dysfunction. Bremelanotide is also FDA-approved as an injection, also called Vyleesi, to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved Vyleesi on June 21, 2019.
-
We're happy to help answer questions you may have, or refer you to a licensed healthcare professional for medical advice. Email us at care@somapeptides.com or schedule a wellness consultation.
Your body, your journey .
Embarking on the journey to better health involves embracing holistic well-being through consultative care. Schedule an appointment with a medical provider to get ongoing support and a treatment plan.